Drug Trial News

RSS

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Molecular insight into how a heart failure drug in clinical trials works

Individuals who have persistent high blood pressure are at increased risks of a number of serious medical conditions, including heart failure.

5 Jan 2009

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma.

5 Jan 2009

Candesartan shown to be safe new therapy for genetic heart disease

A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease.

1 Jan 2009

New therapy for transplant rejection

Researchers in the U.S. have discovered a new cancer drug which effectively treats transplant rejections.

29 Dec 2008

Immunogenicity and safety of human papillomavirus vaccine in healthy boys

New industry-supported research from Finland suggests that Cervarix, an HPV vaccine given to girls in Europe and elsewhere, is safe for boys as well.

21 Dec 2008

Prozac enhances effectiveness of anti-cancer drug

Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer.

18 Dec 2008

Neuralstem files IND for amyotrophic lateral sclerosis stem cell trial

Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

18 Dec 2008

Alfuzosin fails to reduce symptoms in chronic prostatitis

Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug, according to a clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).

18 Dec 2008

Trial tests adult stems cells to treat congestive heart failure

The University of California, San Diego Medical Center is the first hospital in California to enroll patients in a multi-center clinical trial, sponsored by Angioblast Systems Inc., to examine the safety and feasibility of administering adult stems cells to treat congestive heart failure.

18 Dec 2008

Biopure submits IND for trial in patients with acute myeloid leukemia

Biopure Corporation has announced that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)].

17 Dec 2008

Voriconazole effective in combating fungal infections

The effectiveness of voriconazole in combating fungal infections has been confirmed by a new study to be featured in the International Journal of Antimicrobial Agents, published by Elsevier.

16 Dec 2008

Lessons from Northwick Park drug-trial disaster

Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead.

From The University of Manchester 15 Dec 2008

Aspirin does not provide protection against Lynch syndrome

Aspirin, recommended as a preventive approach for patients at risk of hereditary colorectal cancer, does not provide protection against Lynch syndrome, the most common form of hereditary colorectal cancer, according a study published in the Dec. 11 issue of the New England Journal of Medicine.

15 Dec 2008

Three studies of bioTheranostics molecular breast cancer diagnostics presented at symposium

bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company's molecular breast cancer assay to predict risk of disease recurrence in individual patients.

14 Dec 2008

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001).

14 Dec 2008

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

14 Dec 2008

Exparel (DepoBupivacaine) shows promise in hernia repair

A Phase II trial of a single intraoperative administration of Exparel (DepoBupivacaine) resulted in significantly reduced pain with activity in the first 8 to 24 hours following surgery, when pain is generally greatest, compared to conventional treatment.

14 Dec 2008

Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane

An interim analysis of a breast cancer prevention study using exemestane (Aromasin) finds an "acceptable" level of bone loss.

14 Dec 2008

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008